References
- Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol 1992; 24: 174–8
- Brown J M, Lemmon M J, Horsman M R, Lee W W. Structure activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol 1991; 59: 739–48
- Jonsson G G, Kjellen E, Pero R W, Cameron R. Radiosensitization effects of nicotinamide on malignant and normal mouse tissues. Cancer Res 1985; 42: 3944–9
- Horsman M R, Brown D M, Lemmon M, et al. Preferential tumour radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys 1986; 12: 1307–10
- Ben-Hur E, Chen C C, Elkind M. Inhibitors of poly-(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 1985; 45: 2123–7
- Horsman M R, Brown J M, Hirst V K, et al. Mechanism of action of the selective tumour sensitizer nicotinamide. Int J Radiat Oncol Biol Phys 1988; 15: 685–90
- Chaplin D J, Horsman M R, Trotter M J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour. J Natl Cancer Inst 1990; 82: 672–6
- Hirst D G, Kennovin G D, Flitney F W. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br J Radiol 1994; 67: 795–9
- Sensky P L, Prise V E, Tozer G M, Shaffi K M, Hirst D G. Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. Br J Radiol 1993; 67: 1337–41
- Kennovin G D, Flitney F W, Hirst D G. ‘Upstream’ modification of vasoconstrictor responses in rat epigastric artery supplying an implanted tumour. Oxygen Transport to Tissue 1994; 15: 411–6, Vaupel P, et al. eds.
- Trotter M J, Chaplin D J, Durand R E, et al. The use of flourescent probes to identify regions of transient perfusion in murine tumours. Int J Radiat Oncol Biol Phys 1989; 16: 931–4
- Chaplin D J, Horsman M R, Trotter M J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour. J Natl Cancer Inst 1990; 82: 672–6
- Hirst D G, Joiner B, Hirst V K. Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites. Br J Cancer 1993; 67: 1–6
- Horsman M R, Brown J M, Hirst V K, et al. Mechanism of action of the selective tumour radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys 1988; 15: 685–90
- Kelleher D K, Vaupel P. Possible mechanisms involved in tumour radiosensitization following nicotinamide administration. Radiother Oncol 1994; 32: 47–53
- Horsman M R, Christensen K L, Overgaard J. Importance of nicotinamide dose on blood pressure changes in mice and humans. Int J Radiat Oncol Biol Phys 1994; 29: 455–8
- Lee I, Boucher Y, Jain R K. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992; 52: 3237–40
- Stone H B, Minchinton A I, Lemmon M, et al. Pharmacological modification of tumour blood flow: Lack of correlation between alteration of mean arterial blood pressure and changes in tumour perfusion. Int J Radiat Oncol Biol Phys 1991; 22: 79–86
- Boucher Y, Jain R K. Microvascular pressure is the principal driving force for interstitial hypertension. Cancer Res 1992; 52: 5110–4
- Boucher Y, Baxter L T, Jain R K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumours. Cancer Res 1990; 50: 4478–84